Oncorus Stock Price

-0.19 (-11.87%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 2,258,862
Bid Price 1.25
Ask Price 1.48
News -
Day High 1.68


52 Week Range


Day Low 1.41
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncorus Inc ONCR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.19 -11.87% 1.41 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.58 1.41 1.68 1.41 1.60
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,574 2,258,862 $ 1.53 $ 3,446,986 - 0.9827 - 16.18
Last Trade Time Type Quantity Stock Price Currency
18:12:00 10 $ 1.47 USD


Draw Mode:

Oncorus Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 36.50M 25.88M 19.91M $ - $ - -2.55 -0.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 829.50k 2.00%

more financials information »

Oncorus News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONCR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.431.681.261.45300,679-0.02-1.4%
1 Month1.161.900.98271.58416,8760.2521.55%
3 Months1.781.900.98271.50213,078-0.37-20.79%
6 Months5.385.760.98272.03164,406-3.97-73.79%
1 Year15.93516.180.98275.58168,014-14.53-91.15%
3 Years15.5037.86030.982710.74159,341-14.09-90.9%
5 Years15.5037.86030.982710.74159,341-14.09-90.9%

Oncorus Description

Oncorus Inc is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-177; ONCR-GBM; Coxsackievirus A21 and Seneca Valley Virus.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.